



01-02-03

1644

PATENT
674544-2001**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Savage
Serial No. : 09/724,985
Filed : November 28, 2000
Title : METHOD FOR PRODUCING OR ENHANCING A T-CELL
RESPONSE AGAINST A TARGET CELL USING A
COMPLEX COMPRISING AN HLA CLASS I MOLECULE
AND AN ATTACHING MEANS
Group Art Unit : 1644
Examiner : Amy M. DeCloux

AJ
#13
1-13-03

745 Fifth Avenue, New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV196822768US

Date of Deposit: December 31, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Edward Nay

(Typed or printed name of person mailing paper or fee)

Edward Nay

(Signature of person mailing paper or fee)

RECEIVED

JAN 10 2003

TECH CENTER 1600/2900

CLAIM OF PRIORITYCommissioner for Patents
Washington, DC 20231

Sir:

Applicants hereby claim priority under 35 U.S.C. §119, from British application number UK 9812227.8 and UK9908333.9. A certified copy of each is enclosed.

Acknowledgment of the claim of priority and of the receipt of said certified copies are respectfully requested.


Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorney for Applicants

By:

Thomas J. KowalskiThomas J. Kowalski, Reg. No. 32,147
(212) 588-0800

00103967



THIS PAGE BLANK (USPTO)



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

RECEIVED

13 JAN 10 2003

TECH CENTER 1600/2900

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Stephen Hordley

Dated

13 December 2002



THIS PAGE BLANK (USPTO)

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

JRJC/AIW/HP/28303

2. Patent application number

(The Patent Office will fill in this part)

9812227.8

- 5 JUN 1998

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

PHILIP MICHAEL SAVAGE
27 TESTWOOD COURT
GOLDEN MANOR
HANWELL
LONDON W7 3HB

Patents ADP number (*if you know it*)

7451396001

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM.



4. Title of the invention

NOVEL METHOD

5. Name of your agent (*if you have one*)

FJ CLEVELAND

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

40-43 CHANCERY LANE
LONDON
WC2A 1JQ

Patents ADP number (*if you know it*)

0736 885501

141001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

NO

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -
Description 23
Claim(s) -
Abstract -
Drawing(s) 4 + 4

10. If you are also filing any of the following, state how many against each item.

Priority documents -
Translations of priority documents -
Statement of inventorship and right to grant of a patent (Patents Form 7/77) -
Request for preliminary examination and search (Patents Form 9/77) -
Request for substantive examination (Patents Form 10/77) -
Any other documents (please specify) -

11. I/We request the grant of a patent on the basis of this application.
f J Cleveland *f J Cleveland*
Signature Date 5 JUNE 1998
f J CLEVELAND

12. Name and daytime telephone number of person to contact in the United Kingdom
MR JRJ CRUMP, 0171-405-5875

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

NOVEL METHOD

10 This application relates to means for producing or
5 enhancing an immunological response against a target
cell, through the attachment of an immunogenic HLA
class I molecule thereto. The invention is of
potential use in the prevention and treatment of
malignant diseases including cancer and leukaemia,
10 infectious diseases including viral infections such as
HIV, bacterial infections including tuberculosis, and
parasitic infections including malaria.

15 Cytotoxic T cells in the cellular immune system are
responsible for recognising cells that display
"foreign" markings, and triggering an immunological
response against such cells. Each cytotoxic T cell
expresses a number of cell surface recognition
receptors, which recognition receptors all possess
20 precise specificity for a particular "foreign" peptide
sequence, which recognition receptors are adapted to
bind to HLA class I molecules expressed on the surface
of cells scanned by the T cell. HLA class I molecules
are cell surface molecules which possess a peptide
25 binding groove exposed on the external surface of the

cell, which groove is arranged under normal
circumstances to bind a peptide derived from the
interior of the cell. When a recognition receptor on a
cytotoxic T cell binds to an HLA class I molecule on
5 the surface of a scanned cell, the recognition
receptor is enabled to contact the peptide binding
groove of the HLA class I molecule and interact with
any peptide contained therein. If this peptide matches
the specificity of the recognition receptor, the T
10 cell is said to recognise the scanned cell, and may
consequently trigger an immunological response against
said scanned cell.

Cytotoxic T cells of various specificities within a
15 host immune system are also able to recognise and
trigger an immunological response against a cell
exhibiting an HLA class I molecule which is of a
different allotype from the HLA class I molecules of
the host cells. An immunological response of this kind
20 is known as an "alloreactive" response.

An immunological response against a cell usually
results in the lysis of the cell and/or the local
release of cytokines. It has however been observed
25 that cytotoxic T cells do not trigger the lysis of so-

called antigen presenting cells (APCs) in this way. Instead, the immunological response triggered by T cell recognition of an HLA class I molecule on the surface of an antigen-presenting cell results in the direct selective proliferation of the cytotoxic T cell. The host immune system consequently becomes immunised against any cells exhibiting the foreign peptide recognised by the surface recognition receptors on this T cell.

10

It is recognised that the effector mechanisms of the cellular immune system could be a powerful tool in the prevention and treatment of many illnesses, including malignant processes and infectious and auto-immune diseases, including cancer. A small number of the HLA class I molecules on a tumour cell surface may be found to bind peptides which are selectively expressed or over-expressed in tumour cells and are capable of being recognised by cytotoxic T cells in the immune system. Such peptides may furthermore be tumour specific, being found only infrequently, or not at all, on the HLA class I molecules of non-tumour cells. An example of one such tumour specific peptide is the HMW-MAA antigen found on melanoma cells. However, the number of HLA molecules presenting such peptides is

20

25

generally too small to stimulate an effective immunological response against the tumour cell. Moreover, such peptides are rarely, if ever, presented by HLA class I molecules on the surface of APCs.

5

Attempts to enhance the response of the cellular immune system to tumour cells have hitherto focused on increasing tumour cell immunogenicity. In particular, various efforts have been made to produce high-level expression of immunogenic HLA class I molecules on the surface of tumour cells, through the techniques of gene therapy. The delivery of cDNA encoding an HLA class I gene containing an immunogenic peptide in the leader sequence of the HLA molecule has been described in Kang (Cancer Res. 57, 1997, 202-205). Meanwhile, Stopeck (J Clinical Oncology 15, 1997, 341-349) describes the transfection of allogeneic HLA class I in patients with melanoma. This work has demonstrated some response in clinical trials, but has also highlighted the difficulties involved in targeting tumour cells at multiple sites in vivo through the techniques of gene therapy.

20

The present application sets out to provide improved means for producing or enhancing an immunological

25

response against a target cell, and to provide an improved method for treating or preventing cancer and other malignant, infectious or auto-immune diseases.

5 Accordingly, in one aspect of the present invention there is provided a complex comprising an HLA class I molecule or fragment thereof, which HLA class I molecule or fragment thereof comprises a T cell binding portion, and attaching means for selectively
10 attaching said HLA class I molecule or fragment thereof to a target cell.

In another aspect of the present invention there is provided a method of attaching an HLA class I molecule
15 or fragment thereof to a target cell, which HLA class I molecule or fragment thereof comprises a T cell binding portion, comprising the step of introducing to said target cell said HLA class I molecule or fragment thereof and attaching means for selectively attaching
20 said HLA class I molecule or fragment thereof to the target cell.

In yet another aspect of the present invention, there is provided a pharmaceutical composition comprising an
25 HLA class I molecule or fragment thereof, which HLA

class I molecule or fragment thereof comprises a T cell binding portion; attaching means for selectively attaching said HLA class I molecule or fragment thereof to a target cell; and an appropriate excipient or carrier.

The HLA class I molecule or fragment thereof may bind a peptide, which peptide is arranged to be presented for T cell recognition by said HLA class I molecule or fragment thereof. Said peptide may be attached to the HLA class I molecule or fragment thereof in accordance with the method described in Garboczi (PNAS 89, 1992, 3429-3433).

The attaching means preferably comprises a linking polypeptide with high specific affinity for a target cell specific molecule on the surface of the target cell. By "target cell specific molecule" herein is meant any molecule that is characteristically expressed or over-expressed on the surface of the target cell. By way of example, in cancer cells said "target cell specific molecule" could include any of the following antigens: carcinoembryonic antigen, placental alkaline phosphatase, polymorphic epithelial mucin, human chorionic gonadotrophin, CD20, prostate

specific antigen, ca-125, HMW-MAA and others.

Conveniently, the linking polypeptide will comprise an antibody, preferably a monoclonal antibody, raised
5 against said target cell specific molecule. Suitable antibodies for this purpose include C46, 85A12, H17E2, HMFG1, W14, 1F5, 225.28s (Buraggi 1985 Cancer Res. 45, 3378-3387), and others. Deposits of the immortalised hybrids producing these antibodies have been made at
10 the American Type Culture Collection, Rockville MD, USA.

Said linking polypeptide may comprise an antibody raised against a target cell specific molecule and a
15 coupling system for coupling said antibody to said HLA class I molecule or fragment thereof. The coupling system may comprise a two- or three-step chain of well-characterised paired small molecules, joined to the antibody and the HLA class I molecule so as to
20 form a stable bridge between the two. Examples of paired small molecules which might be used in this connection include (but are not limited to) biotin and avidin/streptavidin (Moro, 1997 Cancer Res. 57, 1922-1928), and calmodulin and calmodulin binding peptides
25 (Neri, 1996, J. Invest. Dermatol. 107, 164-170).

Alternatively, said linking polypeptide may comprise an antibody raised against a target cell specific molecule, which antibody is adapted to be attached directly to said HLA class I molecule or fragment thereof.

In a further possible embodiment of the invention, said complex may comprise a recombinant protein, which recombinant protein includes a moiety comprising said HLA class I molecule or fragment thereof, and a moiety comprising said attaching means.

The HLA class I molecule or fragment thereof may be purified from plasma or platelets or made recombinantly. The HLA class I molecule or fragment thereof may further be arranged to bind and present for T cell recognition a defined peptide of choice, such as a viral, bacterial, parasitic, or tumour-specific peptide. Attachment of the HLA class I molecule or fragment thereof to the target cell may be achieved by introducing said HLA class I molecule or fragment thereof and said attaching means to the vicinity of the target cell. The target cell may be a culture cell in vitro, but will advantageously be in the body of a patient. Preferably, the target cell

will be arranged to be contacted by a cytotoxic T cell, which cytotoxic T cell is adapted to recognise said HLA class I molecule or fragment thereof either as being of a mismatched allotype or as binding a foreign peptide, and which cytotoxic T cell is capable of triggering an immunological response against said target cell.

In one embodiment of the present invention the target cell is of a type which may be lysed as a result of an immunological response thereagainst. Advantageously, the target cell is a tumour cell or any diseased or foreign cell the presence of which is undesired in a patient, such as a cancer cell, leukaemia cell, a cell infected with the HIV virus or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, and so on. In order to accelerate the triggering of an immunological response against said target cell in a patient, said HLA class I molecule or fragment thereof will preferably be capable of producing a powerful immune response from the cellular immune system of the patient. Accordingly, said HLA class I molecule or fragment thereof may bind a viral or microbial peptide, preferably a viral or microbial peptide to which the

patient is likely to have had previous exposure. In particular, said HLA class I molecule or fragment thereof may bind an influenza virus peptide, a measles virus peptide, an Epstein-Barr virus peptide, a Cytomegalovirus peptide, or a tetanus toxoid peptide. Alternatively, said HLA class I molecule or fragment thereof may bind any peptide which already has a strong cytotoxic T cell response or which is capable of inducing a powerful immune response. The allotype of said HLA class I molecule or fragment thereof may additionally or alternatively be different from the allotype of the HLA class I molecules of the patient, so that an alloreactive response may additionally or alternatively be triggered against said target cell.

15

In another embodiment of the invention the target cell is an antigen presenting cell (APC). Recognition by a cytotoxic T cell of an HLA class I molecule or fragment thereof attached to said APC may result in direct and selective proliferation of the cytotoxic T cell. Accordingly, said HLA class I molecule or fragment thereof will advantageously be adapted to present for T cell recognition a tumour specific peptide as defined above, or a viral peptide, or a bacterial peptide, or a parasitic peptide, or any

20
25

peptide which is exclusively or characteristically presented by HLA class I molecules on the surface of diseased, malignant or foreign cells the presence of which is undesirable in a patient. Peptides linked to malignant conditions have been characterised (Brossart, 1998 Cancer Res. 58, 732-736 and Lucas, 1998 Cancer Res. 58, 743-752), as have peptides of parasitic origin (Khusmith, 1991 Science 252, 715-718). The attachment of an HLA class I molecule or fragment thereof to an APC, in accordance with the present invention, may be used for in vivo immunisation against cells presenting a given peptide, or ex vivo production of cytotoxic T cells of a particular specificity.

Where the target cell is a tumour cell or microbially infected cell, the pharmaceutical composition of the present invention may be used for the treatment of a tumour or microbial disease respectively, and there is provided a method of treating a tumour or microbial disease in a patient, comprising the step of administering to a patient in need thereof an effective amount of said pharmaceutical composition.

Where the target cell is an APC and the HLA class I

molecule or fragment thereof binds a tumour-specific peptide or any peptide which is exclusively or characteristically presented by HLA class I molecules on the surface of a virally, bacterially, parasitically or microbially infected cell, the pharmaceutical composition of the present invention may be used for immunising against the tumour or viral, bacterial, parasitic or microbial infection respectively, and there is provided a method of immunising against a tumour or viral, bacterial, parasitic or microbial infection in a patient, comprising the step of administering to a patient in need thereof an effective amount of said pharmaceutical composition.

15

The administration of said pharmaceutical composition may be by way of oral, sublingual, transdermal or parenteral administration.

20

Said effective amount of the pharmaceutical composition will depend on factors such as the nature and severity of the disorder being treated and on the weight, age and condition of the patient.

25

For oral or parenteral administration, it is greatly

preferred that the pharmaceutical composition is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.

- 5 Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral preparations, powders, granules, lozenges, reconstitutible powders,
10 injectable and liquid infusible solutions or suspensions or suppositories.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain
15 conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

- 20 Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate.
25 Suitable lubricants include, for example, magnesium

stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling or
5 tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the
10 art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as
15 a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl
20 cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as
25 esters of glycerine, propylene glycol, or ethyl

alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

- 5 Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

For parenteral administration, fluid unit dose forms
10 may be prepared comprising a sterile vehicle. The components of the composition, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the components of the
15 composition in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the
20 composition may be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the compound may be
25 suspended in the vehicle instead of being dissolved

and sterilised by exposure to ethylene oxide before
suspending in the sterile vehicle. Advantageously, a
surfactant or wetting agent may be included in the
composition to facilitate uniform distribution of the
5 compound of the invention.

As is common practice, the compositions will usually
be accompanied by written or printed directions for
use in the treatment concerned.

10

Following is a description, by way of example only,
and with reference to the accompanying drawings, of
methods of putting the present invention into effect.

15 In the drawings :-

Figure 1 shows a diagram showing the method/idea for
delivering HLA molecules to the surface of tumour
cells.

20

Figure 2 shows a FACs analysis of HLA-A2-ve Mel 2
melanoma cells treated with biotin-conjugated
monoclonal antibody 225.28s, avidin, biotin-conjugated
HLA-A2/gag complexes, anti-HLA-A2 monoclonal antibody
25 BB7.2 and phycoerythrin-conjugated rabbit anti-mouse

antibody.

Figure 3 shows the results of a T cell cytotoxicity chromium release assay with Mel 1 cells treated with the delivery system of biotin-conjugated monoclonal antibody 225.28s, avidin, and biotin-conjugated HLA-A2/gag complexes. These cells were incubated with HLA-A2/gag specific cytotoxic T cells with effector/target ratios of 0:1 - 20:1 for 20 hours.

Figure 4 shows a diagram showing the method/idea for delivering HLA class I/peptide complexes to antigen presenting cells.

Example 1

The following components were used:

Target cells : A human melanoma cell line Mel 1, deposited at the Department of Immunology, Institute of Molecular Medicine, Oxford, that carries the HLA class I allotype HLA-A2. The cell line was grown in standard RPMI tissue culture media.

A human melanoma cell line Mel 2,
deposited at the Department of
Immunology, Institute of Molecular
Medicine, Oxford, that does not
5 carry the HLA class I allotype HLA-
A2. The cell line was grown in
standard RPMI tissue culture media.

Attaching means : A monoclonal antibody 225.28s

10 (Buraggi 1985 Cancer Res. 45, 3378-
3387) that binds to the HMW-MAA
antigen on human melanoma cells.
Biotin is chemically conjugated onto
this antibody as described in Bayer
15 1990, Methods Embryology 184, 138-
160.

Pure hen egg avidin obtained
commercially from Societa Prodotti
20 Antibiotici, Milan, Italy.

HLA : Biotin conjugated recombinant HLA
class I allotype HLA-A2 molecules,
as described in Altman 1996, Science
25 274, 94-96, further containing the

"gag" peptide that is part of the HIV virus. This peptide comprises the amino acid sequence -SLYNTVATL-. Methods for the

5 preparation/isolation thereof are described in Johnson 1991, J Immunol 147, 1512. The "gag" peptide was attached to the HLA-A2 molecules as described in Garboczi 1992, PNAS 89, 3429-3433.

10 T cells : HLA-A2/gag specific cytotoxic T cells obtained from an A2+ve HIV patient as described in Altman 1994, Science 274, 94-96.

15 In order to establish the ability of the attaching means to cause display of the HLA class I molecules on the surface of Mel 2 target cells, approximately 20 200,000 cells were first incubated with biotin conjugated monoclonal antibody 225.28s at a final concentration of 20µg/ml at 37°C for 30 minutes. Following this the cells were washed in tissue culture media (RPMI 1640, obtainable from Gibco, Scotland).

25 The Mel 2 cells were then incubated with avidin at a

final concentration of 10µg/ml for 10 minutes at 37°C and washed in tissue culture media. Finally, the Mel 2 cells were incubated with biotin conjugated HLA class I HLA-A2/gag molecules at a final concentration of
5 20µg/ml at 37°C for 20 minutes.

The binding of recombinant HLA-A2 to the treated Mel 2 cells was shown by the attachment of anti-HLA-A2 monoclonal antibody BB7.2 (Santos-Aguado 1988, J. Immunol 141, 2811-2818) following incubation with
10 BB7.2 antibody at a final concentration of 10µg/ml at 37°C for 30 minutes. After washing in tissue culture media the cells were incubated with phycoerythrin conjugated rabbit anti-mouse antibody (Sigma, Poole,
15 UK) at a final concentration of 10µg/ml for 30 minutes at 37°C and analysed in a Becton Dickson Facscan machine. The result of this analysis is shown in Fig 2 which demonstrates a positive signal indicating the presence of HLA-A2 molecules attached to the surface
20 of the Mel 2 cells.

A chromium release T cell cytotoxicity assay was then performed in order to establish the ability of HLA-A2/gag specific T cell clones to lyse Mel 1 cells
25 coated with HLA-A2/gag in accordance with the present

method. Approximately 10^6 Mel 1 cells were first pre-incubated with $1.85\mu\text{Bq Na}_2^{51}\text{CrO}_4$ (obtained from Amersham International, Amersham, UK) for 1 hour at 37°C . The pre-incubated Mel 1 cells were then incubated with
5 biotin conjugated monoclonal antibody 225.28s at a final concentration of $20\mu\text{g/ml}$ at 37°C for 30 minutes, and washed in tissue culture media. Following this, the Mel 1 cells were incubated with avidin at a final concentration of $10\mu\text{g/ml}$ for 10 minutes at 37°C and
10 then washed again in tissue culture media. The Mel 1 cells were then incubated with biotin conjugated HLA class I HLA-A2/gag molecules at a final concentration of $20\mu\text{g/ml}$ at 37°C for 20 minutes and washed with tissue culture media.

15 Having been coated with HLA class I HLA-A2/gag, the chromium-treated Mel 1 cells were then incubated with HLA-A2/gag specific cytotoxic T cells in ratios of 0:1 to 20:1 of effector to target cells at 37°C for 20
20 hours. Lysis of Mel 1 cells treated with $\text{Na}_2^{51}\text{CrO}_4$ results in the release of radioactive chromium, which may be detected by analysis in a scintillation counter.

In order to establish the percentage of Mel 1 cells
25 lysed following incubation with HLA-A2/gag specific

cytotoxic T cells, the following measurements were taken: background release of chromium from the Mel 1 cells in media alone ("M"); release of chromium from the Mel 1 cells following incubation with the T cells ("E"); release of chromium from the Mel 1 cells following final treatment with 5% Triton X-100 detergent ("T"). Treatment with detergent will cause the lysis of all the remaining intact Mel 1 cells.


% Mel 1 lysis by cytotoxic T cells was calculated as follows:

$$\% \text{ lysis} = 100 \times \frac{(E - M)}{(T - M)}$$

This analysis was carried out on Mel 1 cells treated with biotin-conjugated 225.28s, avidin, and biotin-conjugated HLA-A2/gag. As a control, the analysis was also carried out on Mel 1 cells treated with biotin-conjugated 225.28s and avidin alone, and on Mel 1 cells treated with avidin and biotin-conjugated HLA-A2/gag alone.

The key results of this analysis are illustrated in

Figure 3, which indicates that significant lysis (20%) of Mel 1 cells by HLA-A2/gag specific cytotoxic T cells occurs only when the Mel 1 cells have been treated with all the components of the attaching and delivery means of the present invention (ie biotin-conjugated 225.28s monoclonal antibodies, avidin, and biotin-conjugated HLA-A2/gag). No significant increase in cell lysis over background levels was observed in either of the control runs.



THIS PAGE BLANK (USPTO)

1/4






Fig 1

THIS PAGE BLANK (USPTO)

2/4



MM9 melanoma 12.97

Page

Fig 2.

THIS PAGE BLANK (USPTO)

3/4








Fig 3.

THIS PAGE BLANK (USPTO)




□ APC Cell Surface Marker

Calmodulin linked monoclonal antibody

Calmodulin binding peptide linked HLA A2 with "tumour peptide"

T HLA A2 "tumour peptide" specific cytotoxic T cell

Naive T-cell



THIS PAGE BLANK (USPTO)